ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1409.38−1.61 (-0.11%)
Close on Nov 3, 2026Market cap $1.33TP/E 45.7Yield 0.44%
Eli Lilly Trulicity — Outside U.S. revenue by Year
Trulicity — Outside U.S. revenue ($M) ($M)
Eli Lilly Trulicity — Outside U.S. revenue: $1,362M in FY2025, down 12.7% from a year earlier.
Latest, FY2025
1,362
Period ended Dec 31, 2025
Change on a year earlier
-12.7%
1,560 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trulicity — Outside U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,362 | -12.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 1,560 | -8.2% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,699 | -3.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 1,751 | +12.4% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 1,558 | +26.4% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 1,232 | +26.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 973 | +42.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 683 | +62.7% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 420 | +123.5% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 188 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Trulicity — Outside U.S. revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-trulicity-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?